

Objectives: To examine associations between different mindfulness facets, and different aspects of attention and trait impulsivity in BD.

Methods: This study was approved by the Hospital Clínic Ethics and Research Board (HCB/2017/0432). After informed consent, 94 outpatients, M age = 45.57, SD = 9.8, range 19–61 years, 41.5% Male, 63.8% BD-I according to DSM-5 criteria, in partial or total remission based on Young Mania Rating Scale (YMRS; M = 1.81, SD = 2.11) and Hamilton Depression Rating Scale (HDRS; M = 5.46, SD = 3.71) were enrolled in this study. Participants were evaluated using the Five Facet Mindfulness Questionnaire (FFMQ) to assess Mindfulness, the Trail Making Test (TMT-A) and the Conner's Continuous Performance test (CPT-II) to assess Attention, and the Barratt Impulsiveness Scale (BIS-11) to assess Impulsivity. Pearson correlations were performed, and statistical significance was evaluated two-sided at the 5% threshold.

Results: Mindfulness-Describing was negatively associated with Cognitive and Non-Planning Impulsivity (r = -.43 and -.28, p < .001), Mindfulness-Acting with Awareness was negatively associated with Cognitive, Motor and Non-Planning Impulsivity (r = -.27 to -.45, p < .001), Mindfulness Non-Judging (r = -.33 and -.34, p < .001) and Non-Reacting (r = -.30 and -.46, p < .001) of inner experience were negatively associated with Cognitive and Motor Impulsivity. No associations were found between neither Mindfulness nor Impulsivity with any aspects of Attention.

Conclusions: Preliminary findings suggest that better performance in specific facets of mindfulness (describing, acting with awareness, non-judging or reacting of inner experience) may be related to a decrease in different aspects of trait impulsivity. Further longitudinal and interventional research is needed on underlying mechanisms. Nonetheless, our study suggests the need for including mindfulness-based approaches to improve behavioral and functional outcomes for those with BD.

Funding: This work was supported by the European Union Horizon 2020 research and innovation program (EU.3.1.3. Treating and managing disease: Grant 945151), CIBERSAM, FIS PI17/00941 ISCIII, European Regional Development Fund.

References: 1. Carvalho AF, Firth J, Vieta E. Bipolar Disorder. *N Engl J Med*. 2020;383(1):58–66. doi:10.1056/NEJMra1906193

Disclosure of Interest: None Declared

O0058

Psychometric Properties of the Korean Version of Functioning Assessment Short Test in Bipolar Disorder

H. Kang*, B.-H. Yoon, H. Yun, Y. Jeong and J. Song

Psychiatry, Naju national hospital, Naju, Korea, Republic Of

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.263

Introduction: The Functioning Assessment Short Test (FAST) is a relatively specific test for bipolar disorders designed to assess the main functioning problems experienced by patients.

Objectives: FAST includes 24 items assessing impairment or disability in 6 domains of functioning: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal

relationships, and leisure time. It has already been translated into standardized versions in several languages. The aim of this study is to measure the validity and reliability of the Korean version of FAST (K-FAST).

Methods: A total of 209 bipolar disorder patients were recruited from 14 centers in Korea. K-FAST, Young Mania Rating Scale (YMRS), Bipolar Depression Rating Scale (BDRS), Global Assessment of Functioning (GAF) and the World Health Organization Quality of Life Assessment Instrument Brief Form (WHOQOL-BREF) were administered, and psychometric analysis of the K-FAST was conducted

Results: The internal consistency (Cronbach's alpha) of the K-FAST was 0.95. Test-retest reliability analysis showed a strong correlation between the two measures assessed at a 1-week interval (ICC = 0.97; p < 0.001). The K-FAST exhibited significant correlations with GAF (r = -0.771), WHOQOL-BREF (r = -0.326), YMRS (r = 0.509) and BDRS (r = 0.598). A strong negative correlation with GAF pointed to a reasonable degree of concurrent validity. Although the exploratory factor analysis showed 4 factors, the confirmatory factor analysis of questionnaires had a good fit for a six factors model (CFI=0.925; TLI=0.912; RMSEA=0.078).

Table. Model fit index of confirmatory factor analysis (n=209)

Measure of fit	4-factor model	6-factor model	Acceptable value
χ^2/df	2.832	2.267	<3
RMSEA (90% CI)	0.094(0.086-0.102)	0.078 (0.069-0.087)	<0.08
CFI	0.887	0.925	>0.9
TLI	0.873	0.912	>0.9

χ^2 , chi-square; df, degrees of freedom; RMSEA, root mean square error of approximation; CFI, comparative fit index; TLI, Tucker-Lewis index.

Conclusions: The K-FAST has good psychometric properties, good internal consistency, and can be applicable and acceptable to the Korean context.

Disclosure of Interest: None Declared

O0059

Changing trends of suicide mortality from 2011 to 2019: an analysis of 38 European Countries

G. Fico^{1*}, A. Gimenez-Palomo¹, R. Andra Bursan², C. R. Ionescu², F. Kraxner³, P. Rolland⁴, S. Gomes-Rodrigues⁵, M. Batkovic⁶, E. Metaj⁷, S. Tanyeri Kayahan⁸, A. Mamikonyan⁹, P. Paribello¹⁰, A. K. Sikora¹¹, C. M. Platsa¹², M. Spasic Stojakovic¹³, A. H. Halt^{14,15}, M. Az¹⁶, N. Ovelian¹⁷, K. Melamud¹⁸, M. Janusz¹⁹, K. Hinkov²⁰, C. Gramaglia²¹, J. Beezhold²², J. L. Castroman²³, C. Hanon²⁴, D. Eraslan²⁵ and E. Olie²⁶

¹Bipolar and Depressive Disorders Unit - Hospital Clinic of Barcelona - IDIBAPS, Barcelona, Spain; ²"Alexandru Obregia" Clinical Psychiatry Hospital, Bucharest, Romania; ³Department of psychiatry and psychotherapy, Clinical Hospital Affoltern, Zurich, Switzerland;

⁴Academic Psychiatry Department, Centre Hospitalier Guillaume Regnier, Rennes, France; ⁵Child and Adolescent Psychiatry Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; ⁶Psychiatry Department, General Hospital, Dubrovnik, Croatia; ⁷Mia Clinic, Tirana, Albania; ⁸Psychiatry, Turkish Ministry of Health Yalvac Public Hospital, Isparta, Türkiye; ⁹Psychiatry, Yerevan State Medical University after Mkhitar Heratsi, Yerevan, Armenia; ¹⁰Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; ¹¹Addictions and Medical Psychology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine; ¹²Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece; ¹³Institute of Mental Health, Belgrade, Serbia; ¹⁴University of Oulu, Research Unit of Clinical Medicine; ¹⁵Department of Psychiatry, Oulu University Hospital, Oulu, Finland; ¹⁶State Hospital of Abdulkadir Yuksel, Gaziantep, Türkiye; ¹⁷Saint Petersburg State Mental Hospital, Saint Petersburg, Russian Federation; ¹⁸Kharkiv Psychoneurological dispensary, Kharkiv, Ukraine; ¹⁹Instytut Psychiatrii i Neurologii w Warszawie, Warsaw, Poland; ²⁰Etablissement Public de santé Alsace Nord, Strasbourg, France; ²¹Università del Piemonte Orientale, Maggiore della Carità University Hospital, Novara, Italy; ²²Great Yarmouth Acute Service, Northgate Hospital, Great Yarmouth, United Kingdom; ²³Department of Psychiatry, Nîmes University Hospital, France, IGF, Univ. Montpellier, CNRS, INSERM, Montpellier; ²⁴Centre ressource régional de psychiatrie du sujet âgé (CRRPSA), AP-HP, Centre-Université de Paris, Paris, France; ²⁵Istanbul Psikiyatri Enstitüsü, Istanbul, Türkiye and ²⁶Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.264

Introduction: Suicide is a serious public health problem since it accounts for nearly 900,000 deaths each year worldwide. Globally in 2019, 10.7 persons out of 100,000 died by suicide. Psychiatric disorders are related to an overwhelming proportion of these cases. In the last years, several specific interventions and action plans for suicide prevention have been implemented in a number of European countries.


Objectives: Our aim was to analyze recent epidemiologic trends of suicide mortality rates in Europe.

Methods: Annual national statistics of suicide mortality rates derived from Eurostat public databases from 2011 to 2019 were analyzed for 38 European countries. The suicide mortality rate was estimated per year/100,000 population. Linear regression models were used to study temporal trends of suicidal mortality. Analyses were performed using RStudio.

Results: Available data show a statistically significant reduction in suicide mortality rates from 2011 to 2019 in 15 European countries, and a significant increase for Turkey (ES=0.32, SD=0.06, p=0.037) (Fig 1). The greatest significant decrease was reported in Lithuania (ES=-1.42, SD=0.02, p=0.02), followed by Hungary (ES=-1.13, SD=0.11, p=0.0007), Latvia (ES=-0.76, SD=0.11, p=0.007), and Poland (ES=-0.73, SD=0.10, p=0.001). Italy reported the lowest significant reduction in suicide mortality rates (ES=-0.13, SD=0.018, p=0.003). The remaining 16 countries showed no significant changes in suicide mortality trends.

Image:

Figure 1: Suicide Mortality Trends in different European Countries (2011-2019).



Conclusions: In the last years, Europe registered an overall reduction in reported suicide rates. However, more recent data (i.e., suicide rates after COVID-19 pandemic, age and sex-related effect on suicide rates) should be analyzed and used to implement future recommendations. Current and future suicide prevention strategies aim to contribute to a greater reduction of suicide rates in the different European countries.

Disclosure of Interest: None Declared

O0060

Exploring the association among the tryptophan to serotonin and kynurenine pathways, cognition and suicidal behaviour: a secondary analysis in a sample of individuals affected by Bipolar Disorder.

P. Paribello^{1*}, M. Manchia^{1,2}, A. Squassina³, C. Pisanu³, D. Congiu³, S. Dall'Acqua⁴, S. Sut⁴, S. Nasini⁴, M. Garzilli¹, B. Guiso¹, F. Suprani¹, V. Pulcinelli¹, M. N. Iaselli¹, I. Pinna¹, G. Somaini¹, L. Arru¹, C. Corrias¹, F. Pinna¹, S. Comai^{5,6,7} and B. Carpiniello¹

¹Department of Medical Sciences and Public Health, Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy;

²Department of Pharmacology, Dalhousie University, Halifax, Canada;

³Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari;

⁴Department of Pharmaceutical and Pharmacological Sciences;